Table 3.
Name | P‐value | q‐value | Ratioa |
---|---|---|---|
Canonical pathways | |||
Dopamine‐DARPP32 (Dopamine‐ and cAMP‐regulated phosphoprotein, Mr 32 kDa) feedback in cAMP signalling | 4.33×10−5 | 2.31×10−2 | 47/155 (0.303) |
PI3K signalling in B lymphocytes | 1.21×10−4 | 3.07×10−2 | 38/122 (0.311) |
Wnt/β‐catenin signalling | 2.28×10−4 | 3.07×10−2 | 47/165 (0.285) |
Endometrial cancer signalling | 2.30×10−4 | 3.07×10−2 | 20/52 (0.385) |
Protein kinase A signalling | 4.18×10−4 | 3.27×10−2 | 89/368 (0.242) |
Name | P‐value range | q‐value range | No. molecules |
---|---|---|---|
Molecular and cellular functions | |||
Cell‐to‐cell signalling and interaction | 1.72×10−15–5.15×10−3 | 3.71×10−11–2.61×10−1 | 225 |
Cellular assembly and organization | 1.72×10−15–6.83×10−3 | 3.71×10−11–3.01×10−1 | 520 |
Cell death and survival | 8.83×10−8–6.27×10−3 | 1.00×10−4–2.87×10−1 | 924 |
Cell morphology | 2.67×10−6–6.57×10−3 | 1.20×10−3–2.97×10−1 | 662 |
Cellular development | 8.43×10−6–7.42×10−3 | 3.30×10−3–3.19×10−1 | 898 |
Physiological system development and function | |||
Nervous system development and function | 1.72×10−15–7.42×10−3 | 3.71×10−11–3.19×10−1 | 620 |
Tissue morphology | 1.72×10−15–7.24×10−3 | 3.71×10−11–3.15×10−1 | 582 |
Behaviour | 3.48×10−8–6.64×10−3 | 4.69×10−5–2.97×10−1 | 283 |
Embryonic development | 5.97×10−7–7.24×10−3 | 4.37×10−4–3.15×10−1 | 515 |
Organismal development | 5.97×10−7–6.64×10−3 | 4.37×10−4–2.97×10−1 | 711 |
Diseases and disorders | |||
Cancer | 6.66×10−11–6.57×10−3 | 2.06×10−7–2.97×10−1 | 2714 |
Gastrointestinal disease | 6.66×10−11–4.88×10−3 | 2.06×10−7–2.61×10−1 | 2042 |
Organismal injury and abnormalities | 6.66×10−11–7.26×10−3 | 2.06×10−7–3.15×10−1 | 2717 |
Hepatic system disease | 5.72×10−9–2.01×10−8 | 1.24×10−5–2.89×10−5 | 1185 |
Hereditary disorder | 5.79×10−7–6.88×10−3 | 4.37×10−4–3.01×10−1 | 187 |
The ratio indicates the number of molecules associated with a particular pathway, disease or function in the target set compared to the reference set.